View Older Stories View More Recent Stories
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY) Following Expert Call
-
Novo Nordisk jumps, Hims shares plummet after pulling $49 weight-loss pill
-
Eli Lilly & Co. (LLY) call put ratio 1.3 calls to 1 put
-
FDA moves to restrict copycat GLP-1 weight loss drugs
-
Bernstein on Eli Lilly (LLY): 'Raising expectations into 2026'
-
TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)
-
Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
-
Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'
-
Wolfe Research on Eli Lilly (LLY): 'we question the legality of HIMS' ability to market an oral semaglutide'
-
Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'
-
Eli Lilly (LLY) PT Raised to $1,300 at JPMorgan
-
Eli Lilly (LLY) PT Raised to $1,293 at BofA Securities
-
Eli Lilly (LLY) PT Raised to $1,281 at Truist Securities
-
TD Cowen: 'Eli Lilly (LLY) Confident Oral GLP-1s Will Expand Mkt'
-
'Eli Lilly (LLY) Extends Its Lead Into 2026'; PT Raised to $1,300 at BMO Capital
-
Hims stock surges as Wegovy pill copy offered at $49, Novo shares fall
-
Eli Lilly (LLY) PT Raised to $1,260 at Goldman Sachs
-
Deutsche Bank: 'we think the combination of yesterday's day's fear / volatility and today's guide supports a +M/HSD% move for LLY'
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
Bernstein Weighs In on Eli Lilly (LLY) Stock Following Novo Pre-Release
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) Tops Q4 EPS by 34c, Beats on Revenue; Offers FY26 Guidance
-
Stocks expected to have increasing option volume: LLY ABBV UBER BDX JCI AMZN GEHC YUM SU CME UBS BSX QCOM NVS ABBV EA CB CTSH FOXA EFX FTV EMR LUMN SLAB
-
Eli Lilly earnings preview Q4: strong print expected on obesity drugs demand
-
Novo Nordisk shares plunge amid lower 2026 sales outlook
-
Eli Lilly & Co. (LLY) sees volatility amid Novo's warning
-
Veradermics IPO expected to price at top of $14-$16 range
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.3 puts into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1 put into quarter results
-
VeraDermics is said to draw IPO anchor order from Eli Lilly - Bloomberg
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1 put into quarter results
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) call put ratio 1.3 calls to 1 put into quarter results
-
Eli Lilly plans $3.5 billion Pennsylvania manufacturing facility
-
Eli Lilly extends claims data collection to all 340B pharmacy purchases
-
Seamless Therapeutics partners with Eli Lilly on hearing loss gene therapy
-
Walmart raises pharmacy technician wages as it expands healthcare services
-
Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks
-
This U.S. biotech stock is Bernstein's Top Pick for 2026
-
Bernstein on Eli Lilly (LLY): 'Our Top Pick With $1300 PT'
-
Lilly receives FDA breakthrough therapy designation for ovarian cancer drug
-
Eli Lilly (LLY) PT Lowered to $1,161 at Guggenheim
-
Morgan Stanle on Eli Lilly (LLY): 'We see three potential scenarios for REDEFINE4'
-
Eli Lilly & Co. (LLY) call put ratio 1.3 calls to 1 put with a focus as share price up 1.5%
-
Novo Nordisk's oral Wegovy reaches 3,071 prescriptions in first four days
-
FDA delays reviews of Sanofi's Tzield and Disc Medicine's bitopertin
-
BMO Capital on Eli Lilly (LLY): 'We See Strengthening Leadership in Obesity and Beyond in 2026+'
-
Novo Nordisk CEO warns of international competition headwinds, cites Lilly
-
Novo Nordisk (NVO) EVP for product and portfolio strategy: market for oral weight-loss drugs versus injectables bigger than originally thought
-
NVIDIA and Lilly launch $1 billion AI lab for drug discovery
